As a leader in the pharmaceutical industry, TIDE Pharmaceutical R&D center has attracted plenty of talents from top college and research institutions in China, the United States, Japan and many European countries, with over 70% employee are master's degree and doctoral degree holders, which provides a solid foundation for the world class innovation of drug products. The post-doctoral workstation established in the R&D Center is cooperated with top universities and research institutions in China, such as Peking University, Chinese Academy of Sciences, Beijing University of Technology, and West China Hospital Sichuan University. There are 7 postdoctoral fellows in the station, and 2 postdoctoral fellows were graduated. It is planned to recruit 2-3 new postdoctoral fellows each year. The R&D center and Peking University have established a professional master joint talent training program, attracting many top scientific researchers to join TIDE for innovative drug research and development.
TIDE Pharmaceutical R&D Center is focused on four business segments: First-in-class NCE drugs, biological products complex preparation and medical device, in the four therapeutic areas: microcirculation, analgesia, respiration and oncology. The annual R&D expense is 8% of the revenue. R&D center has been awarded "National Enterprise Technology Center", "Beijing Lipid-targeted-formulation Engineering Technology Research Center", "Beijing Hydrogel-polymer Patch Formulation Engineering Technology Research Center", "Beijing Lipid Drug Carrier Innovation Engineering Laboratory", "Beijing Respiratory Disease and High-end Formulation Technology Innovation Center", "Beijing International Science and Technology Cooperation Base of Innovative Formulation”, undertaken several “National and Beijing Science and Technology Major Project” projects, and won the 2019 annual National Science and Technology Progress second prize with “New Drug Preparation Emulsion Key Technologies in System Establishment and Application” . .
Intelligent R&D management system
Top R&D Platform
R&D center area is more than 43,000 m2, designed by the international construction group, KLING STUBBINS, with RMB 530 million investment. It includes drug screening, biological, formulation, and analytical laboratories, as well as pilot plants comply with the Europe and the United States GMP, with all facilities are supplied by the international top vendors, covering the whole life cycle of the drug, from discovery, research, and development to commercialization.
TIDE adheres to the "leading innovation, sustainable innovation" as an important development strategy, the investment in innovative drug research has been increasing, the independent innovation ability has been enhanced. Among them, the platform technology of the R&D center "Establishment and application of key emulsifying technology System in new Pharmaceutical formulation" won the second prize of national Science and Technology Progress award in 2019, and "Industrialization and clinical Application of innovative streptomycin granules conducive to early diagnosis of gastric cancer" won the second prize of Beijing Science and Technology Progress Award in 2019.
The R&D Center has undertaken dozens of National and Beijing major projects, such as the "11th Five-Year Plan", "12th Five-Year Plan", "13th Five-Year Plan", "National Torch Plan", "National International science and Technology Cooperation Project", "National Industrial Foundation Project", "Beijing Science and Technology Plan Project", "Beijing advanced industry development Project" and so on. Most of the R&D products are the first or exclusive innovative projects and have won the Major New Drug Certificate, National Torch Program Project Certificate, Beijing Independent Innovative Product Certificate, Beijing Achievement Award, Beijing New technology and New Product Certificate, etc. So far, 400 invention patents have been applied, among which more than 200 international PCT patents have been applied in more than 20 countries and regions such as the United States, Europe, Japan and Canada.